504 related articles for article (PubMed ID: 20085600)
1. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
Höiby AS; Strand V; Robinson DS; Sager A; Rak S
Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
4. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?
Kepil Özdemir S; Sin BA; Güloğlu D; İkincioğulları A; Gençtürk Z; Mısırlıgil Z
Int Arch Allergy Immunol; 2014; 164(3):237-45. PubMed ID: 25170594
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
6. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
8. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
11. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
12. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
13. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
15. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.
Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C
Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889
[TBL] [Abstract][Full Text] [Related]
17. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
[TBL] [Abstract][Full Text] [Related]
18. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
